Compare Freeport-McMoRan Inc (FCX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Twist Bioscience Corp — how do they compare? Freeport-McMoRan Inc trades at $59.25 (market cap $87.65B), while Twist Bioscience Corp trades at $93.4 (market cap $5.76B). The key difference: Freeport-McMoRan Inc is far larger — about 15.2× Twist Bioscience Corp's market cap, and Freeport-McMoRan Inc pays a 0.98% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| FCX | TWST | |
|---|---|---|
Market Cap | $87.65B | $5.76B |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $102.88 |
52-Week Low | $35.34 | $24.16 |
Enterprise Value | $94.31B | $5.69B |
Dividend Yield | 0.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freeport-McMoRan (FCX) trades at $61.97, up 3.33% with a bearish technical signal despite three consecutive quarterly earnings beats. The copper miner shows improving fundamentals with revenue growth to $25.92B and net income of $2.20B in 2025, supported by strong copper demand. Analyst consensus remains bullish with a $72.94 price target, though the stock faces technical resistance near $63-64 levels.
FCX presents a compelling value proposition with expanding profit margins and strategic positioning in the copper market, though investors face volatility risks from commodity price fluctuations and ongoing negative cash flow trends. The company's expansion pipeline and dividend payments provide additional shareholder value drivers.
Twist Bioscience (TWST) trades at $92.61, up 2.5% on the day, with a bullish technical signal and strong analyst support. The company shows improving revenue growth ($377M in 2025, up 20% year-over-year) but continues to report significant losses (-$77.7M net income). Recent AI-driven drug discovery collaborations and product expansions provide growth catalysts, though persistent negative cash flow and insider selling present concerns.
Outlook remains cautiously optimistic with 79% analyst buy ratings and a $91.63 consensus target. Investment opportunity centers on AI-enabled synthetic biology growth, while risks include sustained profitability challenges, cash burn, and competitive pressures in genomics. The stock trades at premium valuations (P/S 13.74) despite negative margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
